Advertisement

Tumor Biology

, Volume 35, Issue 10, pp 9967–9975 | Cite as

Benzylidenetetralones, cyclic chalcone analogues, induce cell cycle arrest and apoptosis in HCT116 colorectal cancer cells

  • David Drutovic
  • Martina Chripkova
  • Martina Pilatova
  • Peter Kruzliak
  • Pal Perjesi
  • Marek Sarissky
  • Monica Lupi
  • Giovanna Damia
  • Massimo Broggini
  • Jan Mojzis
Research Article

Abstract

Colorectal cancer is the third most common cancer in the world, with 1.2 million new cancer cases annually. Chalcones are secondary metabolite precursors of flavonoids that exhibit diverse biological activities, including antioxidant and antitumor activities. The aim of this study was to investigate the antiproliferative effect of new synthetic chalcone derivatives on HCT116 cells. (E)-2-(2′,4′-dimethoxybenzylidene)-1-tetralone (Q705) was found to be the most active (IC50 = 3.44 ± 0.25 μM). Based on these results, this compound was chosen for further analysis of its biochemical and molecular mechanisms. Our results showed that Q705 inhibited the growth and clonogenicity of HCT116 cells. The results of a flow cytometric analyses suggested that this compound caused a significant cell cycle arrest in G2/M phase and increased the proportion of cells in the subG0/G1 phase, marker of apoptosis. Q705-induced apoptosis was confirmed by TdT-mediated dUTP nick end labelling (TUNEL) assay. Treatment of HCT116 cells with this chalcone significantly increased the caspase-3,-7 activity and resulted in cleavage of poly-ADP-ribose polymerase (PARP). Changes in the nuclear morphology such as chromatin condensation were also observed. These effects were associated with a decreased expression of bcl-xL and increased overall ratio of bax/bcl-xL mRNA levels. Immunofluorescence and qRT-PCR analysis revealed that Q705 induced H2AX histone modifications characteristic of DNA damage, disruption of microtubule organization and downregulation of tubulins. In summary, these results suggest that the cyclic chalcone analogue Q705 has potential as a new compound for colorectal cancer therapy.

Keywords

Benzylidenetetralones Cyclic chalcone analogues Cell cycle arrest Apoptosis Colorectal cancer cells 

Abbreviations

ADP

adenosine diphosphate

cDNA

complementary DNA

Ct

threshold cycle

DNA

deoxyribonucleic acid

dUTP

deoxyuridine triphosphate

FITC

fluorescein isothiocyanate

mRNA

messenger RNA

PCR

polymerase chain reaction

qRT-PCT

quantitative reverse transcription PCR

RNA

ribonucleic acid

TdT

terminal deoxynucleotidyl transferase

Notes

Acknowledgments

This work was supported by SEPO-II (ITMS code: 26220120039) and European Regional Development Fund—Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123). We would like to thank Elisa Caiola and Laura Carrassa for technical support and Tom Billingham for his careful proof-reading of the manuscript.

Conflict of interest

None.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. 2008:CD005390.Google Scholar
  3. 3.
    Wang CZ, Calway TD, Wen XD, Smith J, Yu C, Wang Y, et al. Hydrophobic flavonoids from Scutellaria baicalensis induce colorectal cancer cell apoptosis through a mitochondrial-mediated pathway. Int J Oncol. 2013;42:1018–26.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Velmurugan B, Gangar SC, Kaur M, Tyagi A, Deep G, Agarwal R. Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules. Pharm Res. 2010;27:2085–97.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Kuo YF, Su YZ, Tseng YH, Wang SY, Wang HM, Chueh PJ. Flavokawain B, a novel chalcone from Alpinia pricei Hayata with potent apoptotic activity: involvement of ROS and GADD153 upstream of mitochondria-dependent apoptosis in HCT116 cells. Free Radic Biol Med. 2010;49:214–26.CrossRefPubMedGoogle Scholar
  6. 6.
    Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol. 2007;9:767–76.CrossRefPubMedGoogle Scholar
  7. 7.
    Cassidy CE, Setzer WN. Cancer-relevant biochemical targets of cytotoxic Lonchocarpus flavonoids: a molecular docking analysis. J Mol Model. 2010;16:311–26.CrossRefPubMedGoogle Scholar
  8. 8.
    Tang Y, Li X, Liu Z, Simoneau AR, Xie J, Zi X. Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth. Int J Cancer. 2010;127:1758–68.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Romagnoli R, Baraldi PG, Carrion MD, Cruz-Lopez O, Cara CL, Balzarini J, et al. Hybrid alpha-bromoacryloylamido chalcones. Design, synthesis and biological evaluation. Bioorg Med Chem Lett. 2009;19:2022–8.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Szliszka E, Mazur B, Zydowicz G, Czuba ZP, Krol W. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells. Folia Histochem Cytobiol. 2009;47:579–85.PubMedGoogle Scholar
  11. 11.
    Kim SY, Lee IS, Moon A. 2-Hydroxychalcone and xanthohumol inhibit invasion of triple negative breast cancer cells. Chem Biol Interact. 2013;203:565–72.CrossRefPubMedGoogle Scholar
  12. 12.
    Rao YK, Fang SH, Tzeng YM. Synthesis and biological evaluation of 3′,4′,5′-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation. Bioorg Med Chem. 2009;17:7909–14.CrossRefPubMedGoogle Scholar
  13. 13.
    Ku BM, Ryu HW, Lee YK, Ryu J, Jeong JY, Choi J, et al. 4′-Acetoamido-4-hydroxychalcone, a chalcone derivative, inhibits glioma growth and invasion through regulation of the tropomyosin 1 gene. Biochem Biophys Res Commun. 2010;402:525–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Orlikova B, Tasdemir D, Golais F, Dicato M, Diederich M. The aromatic ketone 4′-hydroxychalcone inhibits TNFalpha-induced NF-kappa B activation via proteasome inhibition. Biochem Pharmacol. 2011;82:620–31.CrossRefPubMedGoogle Scholar
  15. 15.
    Sashidhara KV, Kumar A, Kumar M, Sarkar J, Sinha S. Synthesis and in vitro evaluation of novel coumarin-chalcone hybrids as potential anticancer agents. Bioorg Med Chem Lett. 2010;20:7205–11.CrossRefPubMedGoogle Scholar
  16. 16.
    Mojzis J, Varinska L, Mojzisova G, Kostova I, Mirossay L. Antiangiogenic effects of flavonoids and chalcones. Pharmacol Res. 2008;57:259–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Yadav VR, Prasad S, Sung B, Aggarwal BB. The role of chalcones in suppression of NF-kappaB-mediated inflammation and cancer. Int Immunopharmacol. 2011;11:295–309.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Orlikova B, Tasdemir D, Golais F, Dicato M, Diederich M. Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr. 2011;6:125–47.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Hsu YL, Kuo PL, Tzeng WS, Lin CC. Chalcone inhibits the proliferation of human breast cancer cell by blocking cell cycle progression and inducing apoptosis. Food Chem Toxicol. 2006;44:704–13.CrossRefPubMedGoogle Scholar
  20. 20.
    Zi X, Simoneau AR. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res. 2005;65:3479–86.CrossRefPubMedGoogle Scholar
  21. 21.
    Tabata K, Motani K, Takayanagi N, Nishimura R, Asami S, Kimura Y, et al. Xanthoangelol, a major chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma and leukemia cells. Biol Pharm Bull. 2005;28:1404–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Dimmock JR, Kandepu NM, Nazarali AJ, Kowalchuk TP, Motaganahalli N, Quail JW, et al. Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones. J Med Chem. 1999;42:1358–66.CrossRefPubMedGoogle Scholar
  23. 23.
    Varinska L, van Wijhe M, Belleri M, Mitola S, Perjesi P, Presta M, et al. Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone. Eur J Pharmacol. 2012;691:125–33.CrossRefPubMedGoogle Scholar
  24. 24.
    Dimmock JR, Zello GA, Oloo EO, Quail JW, Kraatz HB, Perjesi P, et al. Correlations between cytotoxicity and topography of some 2-arylidenebenzocycloalkanones determined by x-ray crystallography. J Med Chem. 2002;45:3103–11.CrossRefPubMedGoogle Scholar
  25. 25.
    Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem. 1999;274:22932–40.CrossRefPubMedGoogle Scholar
  26. 26.
    Kaur P, Kaur S, Kumar N, Singh B, Kumar S. Evaluation of antigenotoxic activity of isoliquiritin apioside from Glycyrrhiza glabra L. Toxicol In Vitro. 2009;23:680–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Champelovier P, Chauchet X, Hazane-Puch F, Vergnaud S, Garrel C, Laporte F, et al. Cellular and molecular mechanisms activating the cell death processes by chalcones: critical structural effects. Toxicol In Vitro. 2013;27:2305–15.CrossRefPubMedGoogle Scholar
  28. 28.
    Pilatova M, Varinska L, Perjesi P, Sarissky M, Mirossay L, Solar P, et al. In vitro antiproliferative and antiangiogenic effects of synthetic chalcone analogues. Toxicol In Vitro. 2010;24:1347–55.CrossRefPubMedGoogle Scholar
  29. 29.
    Rozmer Z, Berki T, Perjesi P. Different effects of two cyclic chalcone analogues on cell cycle of Jurkat T cells. Toxicol In Vitro. 2006;20:1354–62.CrossRefPubMedGoogle Scholar
  30. 30.
    Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999;59:1391–9.PubMedGoogle Scholar
  32. 32.
    Krepela E. Cysteine proteinases in tumor cell growth and apoptosis. Neoplasma. 2001;48:332–49.PubMedGoogle Scholar
  33. 33.
    Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Auyeung KK, Ko JK. Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell. Invest New Drugs. 2010;28:1–13.CrossRefPubMedGoogle Scholar
  35. 35.
    Moon DO, Kim MO, Lee JD, Choi YH, Kim GY. Butein suppresses c-Myc-dependent transcription and Akt-dependent phosphorylation of hTERT in human leukemia cells. Cancer Lett. 2009;286:172–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Shin SY, Yoon H, Hwang D, Ahn S, Kim DW, Koh D, et al. Benzochalcones bearing pyrazoline moieties show anti-colorectal cancer activities and selective inhibitory effects on aurora kinases. Bioorg Med Chem. 2013;21:7018–24.CrossRefPubMedGoogle Scholar
  37. 37.
    de Vasconcelos A, Campos VF, Nedel F, Seixas FK, Dellagostin OA, Smith KR, et al. Cytotoxic and apoptotic effects of chalcone derivatives of 2-acetyl thiophene on human colon adenocarcinoma cells. Cell Biochem Funct. 2013;31:289–97.CrossRefPubMedGoogle Scholar
  38. 38.
    Lin E, Lin WH, Wang SY, Chen CS, Liao JW, Chang HW, et al. Flavokawain B inhibits growth of human squamous carcinoma cells: Involvement of apoptosis and cell cycle dysregulation in vitro and in vivo. J Nutr Biochem. 2012;23:368–78.CrossRefPubMedGoogle Scholar
  39. 39.
    Xiao XY, Hao M, Yang XY, Ba Q, Li M, Ni SJ, et al. Licochalcone A inhibits growth of gastric cancer cells by arresting cell cycle progression and inducing apoptosis. Cancer Lett. 2011;302:69–75.CrossRefPubMedGoogle Scholar
  40. 40.
    Ducki S. Antimitotic chalcones and related compounds as inhibitors of tubulin assembly. Anticancer Agents Med Chem. 2009;9:336–47.CrossRefPubMedGoogle Scholar
  41. 41.
    Wang G, Peng F, Cao D, Yang Z, Han X, Liu J, et al. Design, synthesis and biological evaluation of millepachine derivatives as a new class of tubulin polymerization inhibitors. Bioorg Med Chem. 2013;21:6844–54.CrossRefPubMedGoogle Scholar
  42. 42.
    Ducki S, Forrest R, Hadfield JA, Kendall A, Lawrence NJ, McGown AT, et al. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg Med Chem Lett. 1998;8:1051–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998;18:259–96.CrossRefPubMedGoogle Scholar
  44. 44.
    Pasquier E, Andre N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets. 2007;7:566–81.CrossRefPubMedGoogle Scholar
  45. 45.
    Odlo K, Hentzen J. dit Chabert JF, Ducki S, Gani OA, Sylte I, et al. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin. Bioorg Med Chem. 2008;16:4829–38.CrossRefPubMedGoogle Scholar
  46. 46.
    Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 2008;36:5678–94.PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Lavin MF, Birrell G, Chen P, Kozlov S, Scott S, Gueven N. ATM signaling and genomic stability in response to DNA damage. Mutat Res. 2005;569:123–32.CrossRefPubMedGoogle Scholar
  48. 48.
    Sluss HK, Davis RJ. H2AX is a target of the JNK signaling pathway that is required for apoptotic DNA fragmentation. Mol Cell. 2006;23:152–3.CrossRefPubMedGoogle Scholar
  49. 49.
    Li GX, Chen YK, Hou Z, Xiao H, Jin H, Lu G, et al. Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis. 2010;31:902–10.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • David Drutovic
    • 1
  • Martina Chripkova
    • 1
  • Martina Pilatova
    • 1
  • Peter Kruzliak
    • 2
  • Pal Perjesi
    • 3
  • Marek Sarissky
    • 1
  • Monica Lupi
    • 4
  • Giovanna Damia
    • 5
  • Massimo Broggini
    • 5
  • Jan Mojzis
    • 1
  1. 1.Department of Pharmacology, Faculty of MedicinePavol Jozef Šafárik University in KošiceKošiceSlovak Republic
  2. 2.International Clinical Research CenterSt. Anne’s University HospitalBrnoCzech Republic
  3. 3.Institute of Pharmaceutical Chemistry, Faculty of MedicineUniversity of PécsPécsHungary
  4. 4.Laboratory of Cancer Pharmacology, Department of OncologyIRCCS - Istituto di Ricerche Farmacologiche Mario NegriMilanItaly
  5. 5.Laboratory of Molecular Pharmacology, Department of OncologyIRCCS - Istituto di Ricerche Farmacologiche Mario NegriMilanItaly

Personalised recommendations